Iain M MacIntyre1, Emma J Turtle1, Tariq E Farrah2, Catriona Graham3, James W Dear2, David J Webb2. 1. Department of Renal Medicine, Royal Infirmary of Edinburgh, National Health Service Lothian, UK (I.M.M., T.E.F.). 2. University/British Heart Foundation Center of Research Excellence, Center for Cardiovascular Science, Queen's Medical Research Institute (I.M.M., E.J.T., T.E.F., J.W.D., D.J.W.), University of Edinburgh, UK. 3. Edinburgh Clinical Research Facility (C.G.), University of Edinburgh, UK.
Abstract
BACKGROUND: Acetaminophen is widely used as first-line therapy for chronic pain because of its perceived safety and the assumption that, unlike nonsteroidal anti-inflammatory drugs, it has little or no effect on blood pressure (BP). Although observational studies suggest that acetaminophen may increase BP, clinical trials are lacking. We, therefore, studied the effects of regular acetaminophen dosing on BP in individuals with hypertension. METHODS: In this double-blind, placebo-controlled, crossover study, 110 individuals were randomized to receive 1 g acetaminophen 4× daily or matched placebo for 2 weeks followed by a 2-week washout period before crossing over to the alternate treatment. At the beginning and end of each treatment period, 24-hour ambulatory BPs were measured. The primary outcome was a comparison of the change in mean daytime systolic BP from baseline to end of treatment between the placebo and acetaminophen arms. RESULTS: One-hundred three patients completed both arms of the study. Regular acetaminophen, compared with placebo, resulted in a significant increase in mean daytime systolic BP (132.8±10.5 to 136.5±10.1 mm Hg [acetaminophen] vs 133.9±10.3 to 132.5±9.9 mm Hg [placebo]; P<0.0001) with a placebo-corrected increase of 4.7 mm Hg (95% CI, 2.9-6.6) and mean daytime diastolic BP (81.2±8.0 to 82.1±7.8 mm Hg [acetaminophen] vs 81.7±7.9 to 80.9±7.8 mm Hg [placebo]; P=0.005) with a placebo-corrected increase of 1.6 mm Hg (95% CI, 0.5-2.7). Similar findings were seen for 24-hour ambulatory and clinic BPs. CONCLUSIONS: Regular daily intake of 4 g acetaminophen increases systolic BP in individuals with hypertension by ≈5 mm Hg when compared with placebo; this increases cardiovascular risk and calls into question the safety of regular acetaminophen use in this situation. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01997112. URL: https://www.clinicaltrialsregister.eu; Unique identifier: 2013-003204-40.
BACKGROUND: Acetaminophen is widely used as first-line therapy for chronic pain because of its perceived safety and the assumption that, unlike nonsteroidal anti-inflammatory drugs, it has little or no effect on blood pressure (BP). Although observational studies suggest that acetaminophen may increase BP, clinical trials are lacking. We, therefore, studied the effects of regular acetaminophen dosing on BP in individuals with hypertension. METHODS: In this double-blind, placebo-controlled, crossover study, 110 individuals were randomized to receive 1 g acetaminophen 4× daily or matched placebo for 2 weeks followed by a 2-week washout period before crossing over to the alternate treatment. At the beginning and end of each treatment period, 24-hour ambulatory BPs were measured. The primary outcome was a comparison of the change in mean daytime systolic BP from baseline to end of treatment between the placebo and acetaminophen arms. RESULTS: One-hundred three patients completed both arms of the study. Regular acetaminophen, compared with placebo, resulted in a significant increase in mean daytime systolic BP (132.8±10.5 to 136.5±10.1 mm Hg [acetaminophen] vs 133.9±10.3 to 132.5±9.9 mm Hg [placebo]; P<0.0001) with a placebo-corrected increase of 4.7 mm Hg (95% CI, 2.9-6.6) and mean daytime diastolic BP (81.2±8.0 to 82.1±7.8 mm Hg [acetaminophen] vs 81.7±7.9 to 80.9±7.8 mm Hg [placebo]; P=0.005) with a placebo-corrected increase of 1.6 mm Hg (95% CI, 0.5-2.7). Similar findings were seen for 24-hour ambulatory and clinic BPs. CONCLUSIONS: Regular daily intake of 4 g acetaminophen increases systolic BP in individuals with hypertension by ≈5 mm Hg when compared with placebo; this increases cardiovascular risk and calls into question the safety of regular acetaminophen use in this situation. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01997112. URL: https://www.clinicaltrialsregister.eu; Unique identifier: 2013-003204-40.
Authors: Christopher M Williams; Christopher G Maher; Jane Latimer; Andrew J McLachlan; Mark J Hancock; Richard O Day; Chung-Wei Christine Lin Journal: Lancet Date: 2014-07-23 Impact factor: 79.321
Authors: Bruno R da Costa; Stephan Reichenbach; Noah Keller; Linda Nartey; Simon Wandel; Peter Jüni; Sven Trelle Journal: Lancet Date: 2017-07-08 Impact factor: 79.321
Authors: Dena Ettehad; Connor A Emdin; Amit Kiran; Simon G Anderson; Thomas Callender; Jonathan Emberson; John Chalmers; Anthony Rodgers; Kazem Rahimi Journal: Lancet Date: 2015-12-24 Impact factor: 79.321
Authors: Isabella Sudano; Andreas J Flammer; Daniel Périat; Frank Enseleit; Matthias Hermann; Mathias Wolfrum; Astrid Hirt; Priska Kaiser; David Hurlimann; Michel Neidhart; Steffen Gay; Johannes Holzmeister; Juerg Nussberger; Pavani Mocharla; Ulf Landmesser; Sarah R Haile; Roberto Corti; Paul M Vanhoutte; Thomas F Lüscher; Georg Noll; Frank Ruschitzka Journal: Circulation Date: 2010-10-18 Impact factor: 29.690
Authors: Andrew T Chan; JoAnn E Manson; Christine M Albert; Claudia U Chae; Kathryn M Rexrode; Gary C Curhan; Eric B Rimm; Walter C Willett; Charles S Fuchs Journal: Circulation Date: 2006-03-13 Impact factor: 29.690
Authors: Martin Feelisch; Miriam M Cortese-Krott; Jérôme Santolini; Stephen A Wootton; Alan A Jackson Journal: EXCLI J Date: 2022-03-21 Impact factor: 4.022